Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Stereotaxis, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Stereotaxis, Inc.

Regulatory records
4
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 4 FDA records to the applicant name Stereotaxis, Inc.. The collection includes 2 510(k) clearances. It includes 1 original PMA approval. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jan 5, 2026 to Aug 27, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code LPB appears in 2 of the 4 linked filings. The collection spans 3 FDA product codes and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P240014, with 2 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.

Applicant mailing address recorded by FDA: 710 Tucker Blvd., Suite 110, St. Louis, MO, 63101, US. Recorded on K262744, decision dated Aug 27, 2026.

Changes described in PMA records

P240014/S001: MAGiC Ablation Catheter

FDA’s recorded scope: approval of the protocol for the post-approval study (PAS) referenced above. The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P240014.

Jul 31, 2026 · Normal 180 Day Track No User Fee

P240014: MAGiC Ablation Catheter

FDA’s recorded scope: approval for the MAGiC Ablation Catheter. This device is indicated for: The MAGiC Magnetic Interventional Ablation Catheter is indicated for cardiac electrophysiological mapping, delivering diagnostic pacing stimuli, and for the creation of endocardial lesions to treat supraventricular tachycardia (e.g., macroreentrant atrial tachycardia, focal atrial tachycardia, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia) in patients with congenital heart disease in whom vascular or target chamber access by conventional manual catheter navigation is limited due to underlying anatomic abnormalities and/or previous surgical interventions.

Jan 5, 2026

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Stereotaxis, Inc.510(k) clearanceAug 27, 2026FDA
Stereotaxis, Inc.PMA supplementJul 31, 2026FDA
SynchronyK253473
Stereotaxis, Inc.510(k) clearanceApr 1, 2026FDA
Stereotaxis, Inc.PMA approvalJan 5, 2026FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 20, 2026.